Scholars@Duke

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

Publication ,  Journal Article
Published in: New England Journal of Medicine
May 12, 2022
Published version (DOI) Publisher Link

Duke Scholars

Harry Paul Erba
Author Harry Paul Erba Medicine, Hematologic Malignancies and Cellular Therapy

Published In

New England Journal of Medicine

DOI

10.1056/nejmx220003

EISSN

1533-4406

ISSN

0028-4793

Publication Date

May 12, 2022

Volume

386

Issue

19

Start / End Page

1868 / 1868

Publisher

Massachusetts Medical Society

Related Subject Headings

  • General & Internal Medicine
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML. (2022). New England Journal of Medicine, 386(19), 1868–1868. https://doi.org/10.1056/nejmx220003
“Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.” New England Journal of Medicine 386, no. 19 (May 12, 2022): 1868–1868. https://doi.org/10.1056/nejmx220003.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML. New England Journal of Medicine. 2022 May 12;386(19):1868–1868.
“Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.” New England Journal of Medicine, vol. 386, no. 19, Massachusetts Medical Society, May 2022, pp. 1868–1868. Crossref, doi:10.1056/nejmx220003.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML. New England Journal of Medicine. Massachusetts Medical Society; 2022 May 12;386(19):1868–1868.

Published In

New England Journal of Medicine

DOI

10.1056/nejmx220003

EISSN

1533-4406

ISSN

0028-4793

Publication Date

May 12, 2022

Volume

386

Issue

19

Start / End Page

1868 / 1868

Publisher

Massachusetts Medical Society

Related Subject Headings

  • General & Internal Medicine
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences